Skip to main content

Table 1 Clinicopathologic characteristics

From: Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study

CharacteristicPNI negative
(n = 76)
PNI positive
(n = 58)
P
Age (years)57.16 ± 10.2855.34 ± 8.240.273
Male41 (53.9)35 (60.3)0.459
Location  0.781
 Hilar13 (17.1)11 (19.0) 
 Peripheral63 (82.9)47 (81.0) 
HBsAg  0.001
 Negative46 (60.5)50 (86.2) 
 Positive30 (39.5)8 (13.8) 
Tumor size (cm)  0.945
  ≤ 531 (40.8)24 (41.4) 
  > 545 (59.2)34 (58.6) 
Multiple tumor  0.548
 No56 (73.7)40 (69.0) 
 Yes20 (26.3)18 (31.0) 
Vascular invasion  0.148
 No50 (65.8)31 (53.4) 
 Yes26 (34.2)27 (46.6) 
Capsular invasion  0.521
 No39 (51.3)33 (56.9) 
 Yes37 (48.7)25 (43.1) 
Visceral invasion  0.441
 No63 (82.9)45 (77.6) 
 Yes13 (17.1)13 (22.4) 
AJCC T stage  0.486
 1 and 236 (47.4)31 (53.4) 
 3 and 440 (52.6)27 (46.6) 
AJCC N stage  0.503
 052 (68.4)34 (58.6) 
 116 (21.1)16 (27.6) 
 x8 (10.5)8 (13.8) 
AJCC tumor stage  0.672
 I20 (26.3)14 (24.1) 
 II9 (11.8)10 (17.2) 
 III47 (61.8)34 (58.6) 
Tumor differentiation  0.133
 Well to moderate29 (38.2)15 (25.9) 
 Poor to undifferentiated47 (61.8)43 (74.1) 
Liver cirrhosis  0.071
 No45 (59.2)43 (74.1) 
 Yes31 (40.8)15 (25.9) 
ALT (U/L)  0.116
  ≤ 4052 (68.4)32 (55.2) 
  > 4024 (31.6)26 (44.8) 
AST (U/L)  0.656
  ≤ 4050 (65.8)36 (62.1) 
  > 4026 (34.2)22 (37.9) 
PLT (×10^9/L)225.55 ± 92.82231.22 ± 91.170.725
CEA (ng/ml)  0.910
  ≤ 557 (75.0)43 (74.1) 
  > 519 (25.0)15 (25.9) 
CA19–9 (U/ml)  0.017
  ≤ 20051 (67.1)27 (46.6) 
  > 20025 (32.9)31 (53.4) 
CA242 (U/ml)  0.134
  ≤ 2044 (57.9)26 (44.8) 
  > 2032 (42.1)32 (55.2) 
Child-Pugh score  0.259
 A68 (89.5)48 (82.8) 
 B8 (10.5)10 (17.2) 
Postoperative chemotherapy  0.409
 No66 (86.8)53 (91.4) 
 Yes10 (13.2)5 (8.6) 
Post-recurrence anti-tumor therapy  0.987
 Yes51 (67.1)5 (67.2) 
 No25 (32.9)28 (32.8) 
  1. Data are expressed as mean ± standard deviation or n (%)
  2. PNI perineural invasion, HBsAg hepatitis B surface antigen, AJCC American Joint Committee on Cancer, ALT Alanine aminotransferase, AST Aspartate aminotransferase, PLT Blood platelet, CEA Carcinoembryonic antigen;